6 million to develop gene therapy approaches for Duchenne muscular dystrophy viagra.

$1.6 million to develop gene therapy approaches for Duchenne muscular dystrophy, a fatal, childhood-onset disease The Muscular Dystrophy Association has announced it has awarded $1 viagra .6 million to Asklepios, a biotechnology company closely allied with the University of NEW YORK at Chapel Hill, to develop gene therapy strategies for Duchenne muscular dystrophy , a fatal, childhood-onset disease. Without dystrophin, muscle mass cells become fragile, leading to progressive muscle weakness, resulting in wheelchair reliance simply by the death and teenagers from cardiac or respiratory problems by age 30. The disease affects males almost solely.

The most common side effects of Keytruda included fatigue, decreased appetite, shortness of breath or impaired breathing, and cough. The drug also offers the potential to trigger severe immune system-related unwanted effects involving the lungs, colon, hormone-producing glands, nervous system, along with rash and blood vessel inflammation, the FDA said. Pregnant or breast-feeding women should not take the drug because it may harm the fetus or baby, the agency noted. Earlier this full year, the FDA approved the Bristol-Myers Squibb medication Opdivo – – which also targets the PD-1/PD-L1 pathway – – to treat squamous non-small cell lung cancer. Our growing understanding of underlying molecular pathways and how our disease fighting capability interacts with cancer is resulting in important advances in medication, Pazdur said.